Boston Scientific Surpasses Q1 2025 Expectations with Robust Growth and Strategic Advancements
SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has reported strong financial results for the first quarter of 2025, driven by sustained product demand, successful execution of its innovation strategy, and solid geographic performance. The company posted net sales of $4.663 billion, reflecting a 20.9% year-over-year increase on a reported basis, exceeding its own guidance range and affirming its leadership position in the global medical device sector.
Double-Digit Revenue Growth Across Segments and Regions
Boston Scientific achieved broad-based momentum across its business units and global markets:
- MedSurg segment delivered 11.7% reported growth (12.8% operational, 5.3% organic).
- Cardiovascular segment saw standout performance with 26.2% reported growth (27.6% operational, 25.6% organic).
Regional growth highlights included: